Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO GI 2024 | NEST-1: neoadjuvant botensilimab and balstilimab in colorectal cancer

Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, discusses the Phase II NEST-1 trial (NCT05571293) of neoadjuvant botensilimab, a CTLA-4 inhibitor, plus balstilimab, a PD-1 inhibitor, in patients with resectable colorectal cancer. Pathologic responses were promising in patients, especially in patients with microsatellite instability-high (MSI-H) tumors. The study supports further exploration of immunotherapy duration and watch-and-wait strategies for MSI-H patients. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.